Table 1:
Demographic and clinical characteristics of the patients (n = 16)
| Age, years, mean (range) | 58.4 (36.4–72.9) |
| Sex, female, n (%) | 11 (69%) |
| Disease duration, years, mean (range) | 9.6 (0.5–48.0) |
| Erosive disease, n (%) | 7 (44%) |
| Rheumatoid factor positive, n (%) | 11 (69%) |
| CCP-antibody positive, n (%) | 12 (75%) |
| Disease activity (DAS28-4 [CRP]), median (IQR) | 4.4 (3.6–4.9) |
| Swollen joint count, 0–46, median (IQR) | 7 (6–9) |
| Tender joint count, 0–46, median (IQR) | 11 (5–17) |
| Patient’s global assessment, VAS, 0–100 mm, median (IQR) | 35 (31–46) |
| General health, VAS, 0–100 mm, median (IQR) | 51 (37–65) |
| Pain, VAS, 0-100 mm, median (IQR) | 43 (22–64) |
| HAQ disability index, 0–3, median (IQR) | 0.813 (0.625–1.253) |
| csDMARD treatment, n (%) | |
| Single | 3 (19%) |
| Double | 7 (44%) |
| Triple | 6 (37%) |
| Low-dose prednisolone, n (%) | 8 (50%) |
Cyclic citrullinated peptide (CCP); disease activity score for 28 joints (DAS28); interquartile range (IQR); visual analogue scale (VAS); health assessment questionnaire (HAQ); conventional synthetic disease-modifying antirheumatic drug (csDMARD).